Endocrine Abstracts

Background: Psoriasis is associated with a heightened prevalence of cardiovascular risk factors, including metabolic syndrome (MetS). As so far, it is not clear whether MetS will cause differences on clinical outcomes of psoriatic patients who have already suffered from coronary artery disease.

Methods: We conducted a retrospective cohort study to determine the effects of MetS in psoriatic patients with coronary artery disease. Comparisons were made between patients with and without MetS. The Cox regression analysis and Kaplan-Meier survival analysis were used to evaluate the association between variables.

Results: Of the 307 participants, 94 met criteria (30.6%) for MetS. Individuals with MetS were more common in females (P<0.001). The levels of platelet counts and hsCRP were higher in the MetS group (P=0.038 and 0.005, respectively). After the mean follow-up of 35.32±18.61 months, major adverse cardiovascular events (MACEs) and non-fatal myocardial infarction were more prone to occur in MetS group than Non-MetS group (33.3% vs 20.6%, P=0.02; 26.4% vs 15.7%, P=0.032, respectively). Kaplan-Meier estimates showed the same trend. The COX regression analysis showed that MetS [hazard ratio (HR)=1.738, 95% confidence interval (95%CI): 1.045–2.891, P=0.033] and left ventricular ejection fraction (HR=0.968, 95%CI: 0.945–0.991, P=0.006) were associated with an increased risk of MACEs.

Conclusion: In psoriatic patients with coronary artery disease, MetS was more common in females and it independently predicted MACEs. In addition, left ventricular ejection fraction was associated with an increased risk of MACEs. To reduce the cardiovascular disease risk associated with MetS, it is necessary to increase awareness of the condition.